10-K: Eledon Pharma: Tegoprubart Advances, Funding Critical

Eledon Pharmaceuticals' 2025 annual report details promising clinical trial results for tegoprubart in kidney and islet cell transplantation, alongside ongoing financial losses and the need for additional capital.

Summary

• Eledon Pharmaceuticals is a clinical-stage biotechnology company focused on developing tegoprubart, an anti-CD40L antibody, for organ transplantation and ALS.
• The company reported a net loss of $45.6 million for the year ended December 31, 2025, an increase from $36.2 million in 2024.
• Cash and cash equivalents and short-term investments stood at $133.3 million as of December 31, 2025, with an accumulated deficit of $401.2 million.
• Research and development expenses increased by $14.3 million to $66.3 million in 2025, primarily due to increased activity in kidney transplantation trials and manufacturing.
• General and administrative expenses decreased by $1.6 million to $17.0 million in 2025, mainly due to lower stock-based compensation.
• Topline efficacy and safety data from the Phase 2 BESTOW trial for kidney transplant rejection, announced November 6, 2025, showed tegoprubart maintained strong renal function (mean eGFR of ~69 mL/min/1.73 m2 at 12 months) compared to tacrolimus (~66 mL/min/1.73 m2).
• While the primary endpoint in the BESTOW trial did not reach statistical significance, tegoprubart demonstrated non-inferiority for the efficacy failure composite endpoint (22% vs. 17% for tacrolimus) using a 20% non-inferiority margin.
• Tegoprubart showed a favorable safety profile in the BESTOW trial, with significantly lower rates of new-onset diabetes (2% vs. 17%), tremor (1.6% vs. 25.0%), and cardiovascular effects compared to tacrolimus.
• Preliminary data from an investigator-initiated Phase 2 islet cell transplantation study (November 2025) showed all six enrolled subjects achieved insulin independence, with the first three remaining insulin-free for over one year.
• The company has deprioritized and discontinued all clinical development activities for IgA Nephropathy (IgAN) in 2023.
• Eledon Pharmaceuticals is unable to continue clinical development of tegoprubart for ALS without additional financing.
• The company successfully remediated a material weakness in its internal control over financial reporting related to accounting for equity instruments as of December 31, 2025.
• Multiple capital raises occurred in 2023-2025, including a $57.5 million gross proceeds underwritten offering in November 2025, and the company expects to require additional financing to fund future operations beyond the next 12 months.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive due to strong clinical data for tegoprubart in kidney and islet cell transplantation, particularly its safety profile and potential for improved long-term outcomes. However, the increased net loss, higher cash burn, and the stalled ALS program due to financing needs temper the overall sentiment, indicating significant financial hurdles remain despite clinical progress.

Positives

• Tegoprubart demonstrated a favorable safety and tolerability profile compared to tacrolimus in the Phase 2 BESTOW trial, with significantly lower rates of new-onset diabetes (2% vs. 17%), tremor (1.6% vs. 25.0%), and cardiovascular effects.
• Tegoprubart maintained strong renal function in the BESTOW trial, achieving a mean eGFR of approximately 69 mL/min/1.73 m2 at 12 months, which the company believes is one of the highest reported in kidney transplant clinical trials.
• The efficacy failure composite endpoint in the BESTOW trial demonstrated non-inferiority for tegoprubart (22%) versus tacrolimus (17%) using a 20% non-inferiority margin, which the company believes would support approvability if replicated in Phase 3.
• Preliminary data from the investigator-initiated islet cell transplantation study showed promising results, with all six subjects achieving insulin independence and no reported serious infections, thromboembolic events, or biopsy-confirmed rejection events.
• Long-term follow-up data from the Phase 1b kidney transplant trial showed mean eGFR increased from 67.0 mL/min/1.73 m2 at 12 months to 74.2 mL/min/1.73 m2 at 24 months, with no acute rejection, graft loss, death, or new-onset diabetes.
• Tegoprubart has received orphan drug designation from the FDA for ALS and for the prevention of allograft rejection in pancreatic islet cell transplantation.
• The company successfully remediated a previously identified material weakness in its internal control over financial reporting as of December 31, 2025.

Negatives

• The company incurred a net loss of $45.6 million in 2025, an increase of 26% from $36.2 million in 2024.
• Net cash used in operating activities increased to $62.3 million in 2025 from $47.3 million in 2024, indicating a higher cash burn rate.
• The primary endpoint of assessing graft function by eGFR at 12 months in the Phase 2 BESTOW trial did not reach statistical significance.
• The rate of acute rejection in all biopsies was higher in the tegoprubart group (20.6%) compared to the tacrolimus group (14.1%) in the BESTOW trial.
• The company is unable to continue clinical development of tegoprubart for ALS without additional financing specific to that program.
• The company has a significant accumulated deficit of $401.2 million as of December 31, 2025.
• Future issuances of common stock or convertible securities could result in additional dilution for existing stockholders and downward pressure on the stock price.

Risks

• The company's short operating history and shifts in business strategy make it difficult to evaluate future viability.
• Significant operating losses are expected to continue, and profitability may never be achieved or maintained.
• Additional funding will be required to complete the development of the lead drug candidate, and inability to raise capital could force significant alterations to business strategy, curtailment of operations, or liquidation.
• Future issuances of common stock, including from outstanding warrants or convertible securities, could dilute existing stockholders' ownership and cause stock price to fall.
• Product candidates are in early stages of clinical development and may not be successfully developed or commercialized, or may experience significant delays.
• Public health crises, including pandemics or epidemics, could adversely affect business and operations, including research and development activities.
• Unfavorable global economic conditions, including inflation and interest rates, could negatively impact the ability to obtain financing or increase costs.
• Adverse conditions in financial markets, including bank failures, could affect liquidity and financial performance.
• Drug development is a lengthy, expensive process with uncertain outcomes, including failure to demonstrate safety and efficacy to regulatory authorities.
• Results of non-clinical studies and early clinical trials may not be predictive of later-stage clinical trials, and additional safety studies may be required.
• Delays or difficulties in patient enrollment in clinical trials could delay or prevent regulatory approvals and increase expenses.
• Serious adverse events or unacceptable side effects identified during development could lead to abandonment or limitation of product candidate development.
• Future success depends on the ability to retain executives and key employees and to attract, retain, and motivate qualified personnel.
• Failure to obtain, or delays in obtaining, required regulatory approvals, or approvals for narrow indications, could materially impair commercialization and revenue generation.
• Legislation regulating the pharmaceutical and healthcare industries may increase the difficulty and cost of obtaining marketing approval and commercializing product candidates, and affect prices.
• Internal computer systems or those of third parties may fail or suffer security breaches, disrupting development programs or leading to data loss.
• Compromise of privacy, security, integrity, or confidentiality of sensitive information or failure to comply with data privacy obligations could have a material adverse effect.
• Even with marketing approval, product candidates may fail to achieve sufficient market acceptance by physicians, patients, and third-party payers.
• Later discovery of reduced effectiveness or undesirable side effects after marketing approval could compromise the ability to market the product.
• Substantial competition from major pharmaceutical and biotechnology companies, academic institutions, and other organizations exists.
• Uncertainty regarding insurance coverage and reimbursement status of newly approved products could limit marketability and revenue generation.
• Reliance on third parties for manufacturing increases the risk of insufficient quantities, unacceptable cost, or quality issues.
• Dependence on Contract Research Organizations (CROs) and other third parties for testing and development means outcomes are, to an extent, beyond direct control.
• Inability to obtain and maintain intellectual property protection or insufficient scope of protection could allow competitors to commercialize similar products.
• Stock price is expected to be volatile, and the market price of common stock may drop unexpectedly.
• Provisions in corporate charter documents and Delaware law could make an acquisition more difficult and prevent attempts by stockholders to replace management.
• No cash dividends are expected in the foreseeable future, making capital appreciation the sole source of gain for stockholders.

Future Outlook

The company plans to seek guidance from the FDA in 2026 regarding the design of a potential Phase 3 clinical trial for tegoprubart in kidney transplantation and may initiate the trial subject to regulatory feedback and alignment. Continued exploration of xenotransplantation applications is also planned. However, the company will be unable to continue clinical development of tegoprubart for ALS without securing additional financing specific to that program.

Management Comments

• Management believes the central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention.
• The company believes tegoprubart's safety and efficacy results from the Phase 2 BESTOW trial, if replicated in a Phase 3 study, would be sufficient to support its approvability.
• Management believes tegoprubart maintained strong renal function in the BESTOW trial, delivering one of the highest mean eGFR levels reported to date in kidney transplant clinical trials evaluating rejection prevention.
• The company's business strategy is to optimize the clinical and commercial value of tegoprubart and become a global biopharmaceutical company with a focused immunology franchise.
• Management acknowledges the need for additional financing to fund future operations beyond the next 12 months and specifically for the continued clinical development of tegoprubart for ALS.

Industry Context

StockSavvy.ai notes that Eledon Pharmaceuticals operates in a highly competitive biotechnology and pharmaceutical industry, characterized by continuous technological advancement. The focus on CD40L pathway inhibition for immunosuppression in transplantation and neuroinflammation positions tegoprubart against established therapies and numerous pipeline candidates from major pharmaceutical and biotechnology companies like Novartis, Sanofi, and Bristol Myers Squibb. The innovation in immunosuppression, particularly the potential to mitigate side effects associated with calcineurin inhibitors (CNIs) like tacrolimus, addresses a significant unmet medical need in organ transplantation. The emerging field of xenotransplantation also presents a high-risk, high-reward opportunity, with Eledon's collaboration with eGenesis indicating a strategic move into this cutting-edge area. The challenges in ALS development highlight the broader industry's struggle with complex neurodegenerative diseases and the high capital requirements for advancing such programs.

Comparison to Industry Standards

• In the Phase 1b kidney transplant study, tegoprubart-treated patients showed a mean eGFR of approximately 68 mL/min/1.73 m2 through 12 months, which compares favorably to historical studies using CNI-based immunosuppression that typically report aggregate mean eGFRs of approximately 53 mL/min/1.73 m2.
• Abbreviated iBox scores for tegoprubart (-3.75 in ITT, -4.11 on-treatment) compare favorably to a -2.98 historical mean for calcineurin inhibitors, suggesting a predicted 5-year allograft survival rate of over 96% for tegoprubart, indicating potential superiority in long-term graft survival.
• The Phase 2 BESTOW trial demonstrated a significantly better safety profile for tegoprubart compared to tacrolimus, with new-onset diabetes occurring in 2% of tegoprubart patients versus 17% for tacrolimus, and tremor in 1.6% versus 25.0%, addressing key adverse events associated with standard-of-care CNIs.
• Delayed graft function occurred less often with tegoprubart (14.3%) compared to tacrolimus (25%), and required shorter dialysis (4.6 days vs. 6.1 days), suggesting improved early post-transplant outcomes compared to CNI-based regimens.
• Sepsis or bacteremia rates were markedly lower in the tegoprubart arm (4.8%) compared to the tacrolimus arm (17.2%), indicating a potentially reduced risk of serious infections compared to current standards.
• While the primary eGFR endpoint in BESTOW did not reach statistical significance, the company's reported mean eGFR of ~69 mL/min/1.73 m2 for tegoprubart is presented as one of the highest reported to date in kidney transplant clinical trials, suggesting competitive efficacy in renal function maintenance.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for significant dilution from future capital raises, stock price volatility, and no expected cash dividends in the foreseeable future.
• Patients: Potential for improved treatment options for kidney and islet cell transplantation with better safety profiles and long-term outcomes compared to current standard of care. ALS patients face delays in potential new therapies due to funding issues.
• Employees: Continued employment and compensation, but also the impact of strategic shifts and the need for additional financing on job security and growth opportunities.
• Creditors: Exposure to the company's recurring net losses and need for additional funding, though current liquidity is estimated to cover needs for the next 12 months.
• Regulatory Authorities: Ongoing engagement with FDA for clinical trial approvals and guidance, with potential for new regulations to impact development and commercialization costs.

Next Steps

• Seek guidance from the FDA in 2026 regarding the design of a potential Phase 3 clinical trial for tegoprubart in kidney transplantation.
• Potentially initiate a Phase 3 trial for tegoprubart in kidney transplantation, subject to regulatory feedback and alignment.
• Work with key stakeholders on potential next steps to further progress ALS clinical development, contingent on obtaining additional financing.
• Continue to monitor liquidity position and pursue additional financing or other alternatives to fund future operations.

Key Dates

Recommendation

Eledon Pharmaceuticals presents a mixed outlook. The clinical data for tegoprubart in kidney and islet cell transplantation is highly promising, demonstrating a superior safety profile and competitive efficacy compared to existing treatments, with potential for long-term graft survival benefits. This clinical progress is a strong positive for the company's core value proposition. However, the company continues to incur significant operating losses and has a high cash burn rate, necessitating frequent capital raises that lead to substantial shareholder dilution. The primary endpoint miss in the BESTOW trial, despite achieving non-inferiority on the composite endpoint, introduces some uncertainty. Furthermore, the ALS program is stalled due to lack of funding. For a seasoned investor, the clinical upside is compelling, but the financial challenges and early stage of commercialization warrant a cautious 'hold' position until there is clearer visibility on sustained funding, successful Phase 3 outcomes, and a path to profitability.

Keywords

Biotechnology, Immunology, CD40L, Tegoprubart, Kidney Transplantation, Islet Cell Transplantation, ALS, Clinical Trials, Drug Development, SEC Filing, 10-K, Pharmaceuticals, Organ Transplant, Immunosuppression